Quantitative analysis of sponsorship bias in economic studies of antidepressants

Concern is widespread about potential sponsorship influence on research, especially in pharmacoeconomic studies. Quantitative analysis of possible bias in such studies is limited. To determine whether there is an association between sponsorship and quantitative outcomes in pharmacoeconomic studies o...

Full description

Saved in:
Bibliographic Details
Published in:British journal of psychiatry 2003-12, Vol.183 (6), p.498-506
Main Authors: Baker, C Bruce, Johnsrud, Michael T, Crismon, M Lynn, Rosenheck, Robert A, Woods, Scott W
Format: Article
Language:English
Subjects:
Antidepressant drugs
Antidepressants
Antidepressive Agents - economics
Antidepressive Agents - therapeutic use
Antidepressive Agents, Tricyclic - economics
Antidepressive Agents, Tricyclic - therapeutic use
Bias
Biomedical Research - standards
Conflict of Interest
Corporate sponsorship
Cost analysis
Cost control
Cost-Benefit Analysis - methods
Drug Industry
Economic analysis
Economics
Ethics, Research
FDA approval
Financing, Organized - economics
Humans
Medicine
Pharmaceutical industry
Pharmacoeconomics
Pharmacology
Psychiatry
Quantitative analysis
Quantitative research
Research Design - standards
Serotonin reuptake inhibitors
Serotonin uptake inhibitors
Serotonin Uptake Inhibitors - economics
Serotonin Uptake Inhibitors - therapeutic use
Sponsorship
Statistical analysis
Treatment Outcome
Tricyclic antidepressants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Concern is widespread about potential sponsorship influence on research, especially in pharmacoeconomic studies. Quantitative analysis of possible bias in such studies is limited. To determine whether there is an association between sponsorship and quantitative outcomes in pharmacoeconomic studies of antidepressants. Using all identifiable articles with original comparative quantitative cost or cost-effectiveness outcomes for antidepressants, we performed contingency table analyses of study sponsorship and design v. study outcome. Studies sponsored by selective serotonin reuptake inhibitor (SSRI) manufacturers favoured SSRIs over tricyclic antidepressants more than non-industry-sponsored studies. Studies sponsored by manufacturers of newer antidepressants favoured these drugs more than did non-industry-sponsored studies. Among industry-sponsored studies, modelling studies favoured the sponsor's drug more than did administrative studies. Industry-sponsored modelling studies were more favourable to industry than were non-industry-sponsored ones. Pharmacoeconomic studies of antidepressants reveal clear associations of study sponsorship with quantitative outcome.
ISSN:0007-1250
1472-1465
DOI:10.1192/03-2